532 Anti-Viral Therapy and Risk Reduction in Liver Decompensation and Mortality in Hepatitis C Related Cirrhosis- A Systematic Review and Meta-Analysis

2010 ◽  
Vol 138 (5) ◽  
pp. S-789
Author(s):  
Amanpal Singh ◽  
Sarpreet S. Basra ◽  
Gagan Sood
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Risk Reduction ◽  
Meta Analysis ◽  
Liver Decompensation ◽  
Viral Therapy ◽  
Anti Viral Therapy

Systematic review with meta-analysis: Change in liver stiffness during anti-viral therapy in patients with hepatitis B

2018 ◽  
Vol 50 (8) ◽  
pp. 787-794 ◽  
Author(s):  
Antonio Facciorusso ◽  
Herney Andres Garcia Perdomo ◽  
Nicola Muscatiello ◽  
Rosario Vincenzo Buccino ◽  
Vincent Wai-Sun Wong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis B ◽  
Meta Analysis ◽  
Liver Stiffness ◽  
Viral Therapy ◽  
Anti Viral Therapy

scholarly journals Assessing the Clinical Improvement in Patients with COVID-19 using Lopinavir-Ritonavir: A Systematic Review

2021 ◽  
pp. 448-459
Author(s):  
Rania M. Magadmi
Keyword(s):  
Systematic Review ◽  
Statistical Analysis ◽  
Clinical Improvement ◽  
Quantitative Data ◽  
Meta Analysis ◽  
Viral Therapy ◽  
Significant Difference ◽  
Review Study ◽  
Review Manager ◽  
Anti Viral Therapy

Aims: Globally the focus is towards finding an effective treatment for COVID-19 patients in order to suppress the spread of this pandemic disease. An antiviral combination of lopinavir-ritonavir is considered to be effective in treating COVID-19 patients. Therefore, the present study aims to assess the clinical improvements of lopinavir-ritonavir in COVID-19 patients. Study Design: a systematic review study was conducted and articles published since December 2019 were included. The statistical analysis of quantitative data was performed using Review Manager (RevMan) to generate forest plots. Results: The study showed that there was no significant difference in COVID-19 patients treated with lopinavir-ritonavir or in combination with anti-viral therapy or other conventional methods. Conclusion: the use of lopinavir-ritonavir resulted in greater adverse consequences among COVID-19 patients. It further recommends conducting meta-analysis studies with a greater number of studies to highlight the clinical improvement associated with the use of Lopinavir-ritonavir.

Sign in / Sign up

Export Citation Format

Share Document